Cargando…

Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor

BACKGROUND: Oviedomycin is one among several polyketides known for their potential as anticancer agents. The biosynthetic gene cluster (BGC) for oviedomycin is primarily found in Streptomyces antibioticus. However, because this BGC is usually inactive under normal laboratory conditions, it is necess...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Boncheol, Kim, Duck Gyun, Kim, Do-Kyung, Kim, Minji, Kim, Hyun Uk, Oh, Min-Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576301/
https://www.ncbi.nlm.nih.gov/pubmed/37838667
http://dx.doi.org/10.1186/s12934-023-02218-8
_version_ 1785121091334701056
author Gu, Boncheol
Kim, Duck Gyun
Kim, Do-Kyung
Kim, Minji
Kim, Hyun Uk
Oh, Min-Kyu
author_facet Gu, Boncheol
Kim, Duck Gyun
Kim, Do-Kyung
Kim, Minji
Kim, Hyun Uk
Oh, Min-Kyu
author_sort Gu, Boncheol
collection PubMed
description BACKGROUND: Oviedomycin is one among several polyketides known for their potential as anticancer agents. The biosynthetic gene cluster (BGC) for oviedomycin is primarily found in Streptomyces antibioticus. However, because this BGC is usually inactive under normal laboratory conditions, it is necessary to employ systematic metabolic engineering methods, such as heterologous expression, refactoring of BGCs, and optimization of precursor biosynthesis, to allow efficient production of these compounds. RESULTS: Oviedomycin BGC was captured from the genome of Streptomyces antibioticus by a newly constructed plasmid, pCBA, and conjugated into the heterologous strain, S. coelicolor M1152. To increase the production of oviedomycin, clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system was utilized in an in vitro setting to refactor the native promoters within the ovm BGC. The target promoters of refactoring were selected based on examination of factors such as transcription levels and metabolite profiling. Furthermore, genome-scale metabolic simulation was applied to find overexpression targets that could enhance the biosynthesis of precursors or cofactors related to oviedomycin production. The combined approach led to a significant increase in oviedomycin production, reaching up to 670 mg/L, which is the highest titer reported to date. This demonstrates the potential of the approach undertaken in this study. CONCLUSIONS: The metabolic engineering approach used in this study led to the successful production of a valuable polyketide, oviedomycin, via BGC cloning, promoter refactoring, and gene manipulation of host metabolism aided by genome-scale metabolic simulation. This approach can be also useful for the efficient production of other secondary molecules encoded by ‘silent’ BGCs. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-023-02218-8.
format Online
Article
Text
id pubmed-10576301
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105763012023-10-15 Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor Gu, Boncheol Kim, Duck Gyun Kim, Do-Kyung Kim, Minji Kim, Hyun Uk Oh, Min-Kyu Microb Cell Fact Research BACKGROUND: Oviedomycin is one among several polyketides known for their potential as anticancer agents. The biosynthetic gene cluster (BGC) for oviedomycin is primarily found in Streptomyces antibioticus. However, because this BGC is usually inactive under normal laboratory conditions, it is necessary to employ systematic metabolic engineering methods, such as heterologous expression, refactoring of BGCs, and optimization of precursor biosynthesis, to allow efficient production of these compounds. RESULTS: Oviedomycin BGC was captured from the genome of Streptomyces antibioticus by a newly constructed plasmid, pCBA, and conjugated into the heterologous strain, S. coelicolor M1152. To increase the production of oviedomycin, clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system was utilized in an in vitro setting to refactor the native promoters within the ovm BGC. The target promoters of refactoring were selected based on examination of factors such as transcription levels and metabolite profiling. Furthermore, genome-scale metabolic simulation was applied to find overexpression targets that could enhance the biosynthesis of precursors or cofactors related to oviedomycin production. The combined approach led to a significant increase in oviedomycin production, reaching up to 670 mg/L, which is the highest titer reported to date. This demonstrates the potential of the approach undertaken in this study. CONCLUSIONS: The metabolic engineering approach used in this study led to the successful production of a valuable polyketide, oviedomycin, via BGC cloning, promoter refactoring, and gene manipulation of host metabolism aided by genome-scale metabolic simulation. This approach can be also useful for the efficient production of other secondary molecules encoded by ‘silent’ BGCs. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-023-02218-8. BioMed Central 2023-10-14 /pmc/articles/PMC10576301/ /pubmed/37838667 http://dx.doi.org/10.1186/s12934-023-02218-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Gu, Boncheol
Kim, Duck Gyun
Kim, Do-Kyung
Kim, Minji
Kim, Hyun Uk
Oh, Min-Kyu
Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor
title Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor
title_full Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor
title_fullStr Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor
title_full_unstemmed Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor
title_short Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor
title_sort heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain streptomyces coelicolor
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576301/
https://www.ncbi.nlm.nih.gov/pubmed/37838667
http://dx.doi.org/10.1186/s12934-023-02218-8
work_keys_str_mv AT guboncheol heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor
AT kimduckgyun heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor
AT kimdokyung heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor
AT kimminji heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor
AT kimhyunuk heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor
AT ohminkyu heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor